Bone tumors in adolescents and young adults

Current Treatment Options in Oncology

Volumn 9, Issue 1, 2008, Pages 67-80

  Bielack, Stefan S ^a   Carrle, Dorothe ^b   Hardes, Jendrik ^b   Schuck, Andreas ^b   Paulussen, Michael ^c  

^a OLGAHOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CARBOXYPEPTIDASE G2; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETHANOLAMINE; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MURAMYL TRIPEPTIDE; PACLITAXEL; PEGINTERFERON ALPHA; TOPOTECAN; VINCRISTINE;

ADD ON THERAPY; ADOLESCENT; ADULT; ARTICLE; BONE MATURATION; BONE TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; EWING SARCOMA; HUMAN; LIMB MOVEMENT; LIMB SALVAGE; LOCAL THERAPY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OSTEOSARCOMA; PATIENT CARE; PRACTICE GUIDELINE; PRIMARY TUMOR; PROGNOSIS; TREATMENT INDICATION; CHILD; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; SARCOMA;

ADULT; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; HUMANS; SARCOMA;

EID: 47049131487     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-008-0057-1     Document Type: Article

References (71)

1. Gloeckler Ries LA, Reichman ME, Riedel Lewis D, Hankey BF, Edwards BK: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541-552
2. Bleyer A, Viny A, Barr R: Cancer in 15- to 29-year-olds by primary site. Oncologist 2006, 11:590-601
3. Fletcher CDM, Unni KK, Mertens F: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 225-419
4. Chow WA: Update on chondrosarcomas. Curr Opin Oncol 2007, 19:371-376
5. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E: Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006, 42:2124-2135
6. Bleyer A, Montello M, Budd T, Saxman S: National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer 2005, 103:1891-1897
7. Bielack SS, Kempf-Bielack B, Delling G, et al.: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2002, 20:776-790
8. Bielack SS, Machatschek JN, Flege S, Jürgens H: Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004, 5:1243-1256
9. Kager L, Zoubek A, Pötschger U, et al.: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003, 21:2011-2018
10. Kager L, Zoubek A, Kastner U, et al.: Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006, 24:1535-1541
11. Goorin AM, Schwartzentruber DJ, Devidas M, et al.: Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003, 21:1574-1580
12. Fuchs N, Bielack SS, Epler D, et al.: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998 9:893-899
13. Bacci G, Briccoli A, Ferrari S, et al.: Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001, 37:2030-2039
14. Smeland S, Muller C, Alvegard TA, et al.: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003, 39:488-494
15. Ferrari S, Smeland S, Mercuri M, et al.: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005, 23:8845-8852
16. Petrilli AS, de Camargo B, Filho VO, et al.: Results of the Brazilian Osteosarcoma Treatment Group studies III and IV: Prognostic factors and impact on survival. J Clin Oncol 2006, 24:1161-1168
17. Le DeAey MC, Guinebretière JM, Gentet JC, et al.: SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007, 43:752-761
18. Lewis IJ, Nooij MA, Whelan J, et al.: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-128
19. Meyers PA, Schwartz CL, Krailo M, et al.: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23:2004-2011
20. Meyers PT, Schwartz C, Krailo M, et al.: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children's Oncology Group. J Clin Oncol 2008, 26:633-638
21. Longhi A, Ferrari S, Bacci G, Specchia S: Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drug 2007, 18:737-744
22. Aquerreta I, Aldaz A, Giràldez J, Sierrasesúmaga L: Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatr Blood Cancer 2004, 42:52-58
23. Crews KR, Liu T, Rodriguez-Galindo C, et al.: High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004, 100:1724-1733
24. Zelcer S, Kellick M, Wexler LH, et al.: Methotrexate levels and outcome in osteosarcoma. Pediatr Blood Cancer 2005, 44:638-642
25. Tunn PU, Reichardt P: Chemotherapy for osteosarcoma without high-dose methotrexate: A 12-year follow-up on 53 patients. Onkologie 2007, 30:228-232
26. Widemann BC, Balis FM, Kempf-Bielack B, et al.: High-dose methotrexate-induced nephrotoxicity: Incidence in osteosarcoma. Patients, treatment and outcome. Cancer 2004, 100:2222-2232
27. Flombaum CD, Meyers PA: High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999, 17:1589-1594
28. Lewis IJ, Weeden S, Machin D, et al.: Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol 2000, 18:4028-4037
29. Eselgrim M, Grunert H, Kühne T, et al.: Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 2006, 47:42-50
30. Sauerbrey A, Bielack S, Kempf-Bielack B, et al.: High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001, 27:933-937
31. Fagioli F, Aglietta M, Tienghi A, et al.: High-dose chemotherapy in the treatment of relapsed osteosarcoma: An italian sarcoma group study. J Clin Oncol 2002, 20:2150-2156
32. Carrle D, Dantonello T, Bielack SS: Meeting report: Pan-European Sarcoma Trials: Moving forward in a climate of increasing economic and regulatory pressure. Sarcoma 2007, Article ID 76405, 7 pages, doi: 10.1155/2007/76405
33. Goorin AM, Harris MB, Bernstein M, et al.: Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial. J Clin Oncol 2002, 20:426-433
34. Müller CR, Smeland S, Bauer HC, Saeter G, Strander H: Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series. Acta Oncol 2005, 44:475-480
35. Craft A, Cotterill S, Malcolm A, et al.: Ifosfamide-containing chemotherapy in Ewing's sarcoma: The second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998, 16:3628-3633
36. Oberlin O, Deley MC, Bui BN, et al.: Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: The third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001, 85:1646-1654
37. Paulussen M, Ahrens S, Dunst J, et al.: Localized Ewing tumor of bone: Final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol 2001, 19:1818-1829
38. Grier HE, Krailo MD, Tarbell NJ, et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694-701
39. Euro-E.W.I.N.G.Study Committee: EURO-E.W.I.N.G. 99 Study Manual-EUROpean Ewing Tumour Initiative of National Groups Ewing Tumour Studies 1999. http://euro-ewing.uni-muenster.de/, 2007
40. Cangir A, Vietti TJ, Gehan EA, et al.: Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990, 66:887-893
41. Paulussen M, Ahrens S, Burdach S, et al.: Primary metastatic (stage IV) Ewing tumor. Survival analysis of 171 patients from the EICESS studies. Ann Oncol 1998, 9:275-281
42. Meyers PA: High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004, 16:120-125
43. Jürgens C, Weston C, Lewins I, et al.: Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006, 47:22-29
44. Manfrini M: The role of vascularized fibula in skeletal reconstruction. Chir Organi Mov 2003, 88:137-142
45. Hardes J, Gebert C, Hillmann A, et al.: Die Möglichkeiten und Grenzen der Umkehrplastik im operativen Behandlungsplan der primär malignen Knochentumoren. Orthopäde 2003, 32:965-970
46. Baumgart R, Hinterwimmer S, Krammer M, et al.: The bioexpandable prosthesis: A new perspective after resection of malignant bone tumors in children. J Pediatr Hematol Oncol 2005, 27:452-455
47. Krepler P, Dominkus M, Toma CD, et al.: Endoprosthesis management of the extremities of children after resection of primary malignant bone tumors. Orthopäde 2003, 32:1013-1019
48. Abudu A, Grimer RJ, Tillman R, et al.: The use of prostheses in skeletally immature patients. Orthop Clin North Am 2006, 37:75-84
49. De Wilde L, Sys G, Julien Y, et al.: The reversed Delta shoulder prosthesis in reconstruction of the proximal humerus after tumour resection. Acta Orthop Belg 2003, 69:495-500
50. Gosheger G, Hardes J, Ahrens H, et al.: Silver-coated megaendoprostheses in a rabbit model-an analysis of the infection rate and toxicological side-effects. Biomaterials 2004, 25:5547-5556
51. Bacci F, Ferrari S, Longhi A, et al.: Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep 2004, 11:111-120
52. Schuck A, Hofmann J, Rube C, et al.: Radiotherapy in Ewing's sarcoma and PNET of the chest wall: Results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys 1998, 42:1001-1006
53. Schuck A, Ahrens S, Paulussen M, et al.: Local therapy in localized Ewing tumors: Results of 1.058 patients treated in the CESS 81, CESS 86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003, 55:168-177
54. Bacci G, Longhi A, Briccoli A, et al.: The role of surgical margins in treatment of Ewing's sarcoma family tumors: Experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Incol Biol Phys 2006, 65:766-772
55. Krasin M, Rodriguez-Galindo C, Billups C, et al.: Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: Outcome and prognostic factors. Int J Radiat Oncol Biol Phys 2004, 60:830-838
56. Paulino A, Nguyen T, Mai W, The B, Wen B. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 2007, 49:145-148
57. Machak GN, Tkachev SI, Solovyev YN, et al.: Neoadjuvant chemotherapy and local radiotherapy for high grade osteosarcoma of the extremities. Mayo Clin Proc 2003, 78:147-155
58. DeLaney TF, Park L, Goldberg SI, et al.: Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 2005, 61:492-498
59. Kempf-Bielack B, Bielack SS, Jürgens H, et al.: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005, 20(23):559-568
60. Ferrari S, Briccoli A, Mercuri M, et al.: Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003, 21:710-715
61. Meyer WH, Pratt CB, Poquette CA, et al.: Carboplatin/ifosfamide window therapy for osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001, 19:171-182
62. Saylors RL III, Stine KC, Sullivan J, et al.: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001, 19:3463-3469
63. Anderson P, Nuñez R: SaSarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 2007, 7:1517-1527
64. Whelan JS, McTiernan A, Kakouri E, et al.: Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 2004, 43:237-242
65. Wagner LM, McAllister N, Goldsby RE, et al.: Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007, 48:132-139
66. Maksimenko A, Malvy C: Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma. Expert Opin Ther Targets 2005, 9:825-830
67. Martins AS, Mackintosh C, Martin DH, et al.: Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532-3540
68. Lissat A, Vraetz T, Tsokos M, et al.: Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 2007;170:1917-1930
69. Myatt SS, Burchill SA: The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity. Oncogene 2007, 7:985-996
70. Völker T, Denecke T, Steffen I, et al.: Positron emission tomography for staging of pediatric sarcoma patients: Results of a prospective multicenter trial. J Clin Oncol 2007, 25:5435-5441
71. Schuetze MS: Utility of PET in sarcomas. Current Opin Oncol 2006, 18:369-373